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Introduction: Some non-steroidal anti-inflammatory drugs (NSAIDs) delay
healing of experimental gastric ulcers. The two experimental NSAIDs
tebufelone and nitrofenac exert relatively low ulcerogenicity in various animal
models compared with conventional NSAIDs. In addition, it has been reported
that nitrofenac accelerates experimental acute ulcer healing. However, the
effects ofthese new NSAIDs in a reliable chronic ulcer model has not been fully
established.
Methods: Ulcerogenicity of tebufelone was compared with vehicle and
indomethacin in arthritic female Lewis rats in a single dose and a 5-day dosage
study. Interference with ulcer healing of tebufelone and nitrofenac was com-
pared with vehicle, indomethacin, diclofenac, omeprazole, and indomethacin
plus omeprazole in Wistar rats with gastric cryo-ulcers. The rats were treated for
15 days and ulcer size was sequentially quantified by video endoscopy.
Prostanoid synthesis in stomach and blood were assessed on day 15.
Results: Ulcerogenicity of tebufelone was markedly lower than that of
indomethacin using doses with equipotent anti-inflammatory activities. Ulcer
healing was accelerated by omeprazole in the first week, but significantly
delayed by tebufelone and nitrofenac to a similar extent as indomethacin and
diclofenac predominantly during the second week. All NSAIDs decreased
prostanoid synthesis.
Conclusion: Tebufelone and nitrofenac delayed gastric ulcer healing to a simi-
lar extent as conventional NSAIDs even though tebufelone appears to induce
less mucosal damage when determined in standard ulcer assays in rats. Thus
there does not appear to be a relationship between ulcerogenicity of these
NSAIDs and their behaviour in ulcer healing.
INTRODUCTION
Chronic infection with Helicobacter pylori and non-steroidal anti-inflammatory
drugs (NSAIDs)e represent the two most important pathogenetic factors in peptic ulcer
disease [1-3]. Since eradication ofH. pylori can cure peptic ulcer disease in the majority
of H. pylori-associated peptic ulcers, increasingly more attention is given to prevention
and therapy ofNSAID induced ulcers. This is ofparticular importance since NSAIDs are
highly liable to produce severe ulcer complications such as massive gastrointestinal hem-
orrhage or perforation from complicatied peptic ulcers [4, 5]. It is now increasingly rec-
ognized that the occurence ofsuch complications is not restricted to the stomach and duo-
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denum but can also result from ulcers localized in the small and large bowel [6]. Chronic
administration ofNSAIDs produces gastroduodenal mucosal erosions in 35-60 percent of
patients, ulcerations in 10-25 percent, and severe gastrointestinal hemorrhage or perfora-
tion in less than1 percent [2, 4,5]. In experimental and clinical conditions, indomethacin
delays gastric ulcer healing [7, 8]. Among the mechanisms proposed for delayed healing
are: (1) inhibition of synthesis of prostaglandins that are important for gastroduodenal
mucosal defense [9, 10], (2) inhibition ofepithelial cell proliferation in the ulcer margin
that is critical forre-epithelialization of the ulcer crater [7, 11, 12], (3) inhibition of angio-
genesis that is essential for nutrient supply in the ulcer bed [1] and, (4) inhibition ofpro-
liferation and function of myofibroblasts involved in remodeling and contraction of the
granulation tissue in the ulcer bed[11, 13].
NSAIDs inhibit prostaglandin synthesis by the gastric mucosa and thromboxane pro-
duction by platelets so impairing platelet aggregation. Within 90 minutes of acute aspirin
ingestion in humans extensive intramucosal petechial hemorrhage occurs visibly and this
may, in part, be related to promotion ofbleeding from the antiplatelet actions of aspirin.
Withlongerterm ofingestion, the number oferosions may diminish, possibly by a process
ofadaptation [14]. However, erosions, petechiae andsuperficial ulcers are quite common
in patients on long-term maintenance treatment with NSAIDs. Moreover, it is not estab-
lished why a small proportion ofpatients develop chronic ulcers yet others exhibit little or
no mucosal damage.
In the last decade or so, there have been major efforts to reduce the gastroduodenal
toxicity of NSAIDs. Much work has concentrated on use of co-prescribed mucosal pro-
tective agents. Thus, endoscopic studies have shown that the prostaglandin analogue miso-
prostol reduces the incidence ofgastric and duodenal ulcers and the admission rate to hos-
pital with ulcer complications [10]. Prostaglandins did not, however, meet their expecta-
tions in healing of peptic ulcers, they only exert modest ulcer healing at acid inhibitory
doses [15]. Profound acid suppression by proton pump inhibitors is, however, highly
effective in the treatment ofNSAID-induced gastroduodenal ulcerations both in man and
experimental models [7, 11, 16, 17] but long term anacidity may prove undesirable side-
effects (e.g., promotion of bacterial overgrowth).
Numerous strategies have been used in recent years to develop new anti-inflammato-
ry and analgesic drugs that spare the gastrointestinal tract. Several groups are attempting
to develop NSAIDs that predominantly inhibit effects on lipoxygenase or other particu-
larly non-ulcerogenic pathways oflipid metabolism and/or which have antioxidant activ-
ity. Tebufelone has been shown to be gastroprotective in various models of NSAID-
inducedinjury [18]. We reasoned thattheuniquepharmacological properties oftebufelone
having differential effects on lipoxygenase pathways and/or antioxidant effects might
influence ulcerhealing aspart ofthe overall anti-ulcer effects seen with these compounds.
Anotherstrategy fordeveloping gastrointestinal-sparing NSAIDs is the coupling of a
nitricoxide-releasing moiety to a standard NSAID [19-26]. The rationale behind this strat-
egy is that the nitric oxide (NO) released from these derivatives will exert beneficial
effects on the mucosaby maintaininggastrointestinal blood flow and inhibiting adherence
and activation of white blood cells with the gastrointestinal mucosa [19, 20]. One such
NO-releasing NSAID is nitrofenac, this being the NO-donor of the NSAID, diclofenac.
Hypothesis: a) Antioxidant activity and/or effects on lipoxygenase or other pathways
oflipid metabolism affected by tebufelone might decrease ulcerogenic damage and inter-
feres with gastric ulcer healing to a lesser extent compared with conventional NSAIDs,
and b) nitrofenac may interfere with chronic gastric ulcer healing to a lesser extent com-
pared with diclofenac consequent upon NO-donation from nitrofenac.
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MATERIALS AND METHODS
L Comparative ulcerogenicity oftebufelone andreference NSAIDs in arthritic rats with an
intact stomach
Animals: The model of adjuvant-induced arthritis was employed as this is known to
be more sensitive to the ulcerogenic effects ofNSAIDs [27, 28]. Moreover, this is a model
ofpolyarthritis resembling rheumatoid and related arthritic conditions in humans, and thus
has direct clinical relevance [27]. Tests of NSAIDs in this animal model can be consid-
ered representative of their chronic ulcerogenicity in arthritic disease. Female Lewis rats
(Specific pathogen-free, from Charles River) were injected with heat-killed
Mycobacterium butyricum (Difco) 0.5 mg in 0.05 ml squalene (Sigma) [29] then used at
14-16 day post-induction i.e., after injection ofthe adjuvant. Those animals exhibiting full
manifestation of polyarthritis were selected for subsequent use. Two treatment groups
were employed:
Single dose study: Animals were prior fasted for 24 hrs then given a single oral dose
of test drugs. They were killed at 2 and 4 hrs (to ensure that the time of peak ulcero-
genicity ofthe drugs related to the peakperiods ofgastric absorption). The gastric mucosa
was removed and the lesion area and numbers quantified as described [31].
S-day dosage study: The rats were dosed orally with the drugs each day for a total of
5 days. They were then fasted for approximately 20 hrs on day 4 prior to the final dose
and then killed 4 hrs after the final dose of drug. The intestinal tract as well as the stom-
ach of these animals was removed and the area and number of lesions quantified. It was
important to establish the ulcerogenicity in the intestinal tract since recent studies suggest
that this may be a more significant site of ulcerogenicity in arthritic patients than recog-
nized for many NSAIDs [29].
Testdrugs anddosing: All drugs were prepared immediately before dosing in 0.5 per-
centTween 20 with 1 percent carboxymethyl-cellulose at doses as follows: Tebufelone 15,
50, 250, or 500 mg/kg per os in single dose studies and 15 or 50 mg/kg/day per os in
5-day dosage group. Indomethacin 5, 10, or 30 mg/kg per os in single dose experiments;
1, or 3.0 mg/kg/day per os in 5-day dosage group; high doses are inevitably fatal because
ofperitonitis from this drug. Control animals received 1 ml 1 percent carboxymethyl-cel-
lulose plus 0.5 percent Tween 20 in water per 200 g body weightper os. At least 3-7 ani-
mals were employed per group.
These studies were approved by the Annual Research Experimentation Board of
McMaster University, Hamilton, Ontario, Canada.
I. Ulcer healing studies with new generation and reference NSAIDs
Ulcer induction: This study was approved by the Animal Study Committee of the
University of Bern, Switzerland. A gastric cannula (steel, inner diameter 8 mm, exterior-
ly fitted with a screwed on cap, Band, Bern, Switzerland [11, 31] allowing video endo-
scopic examination ofthe gastric mucosa, was placed into the lumen offemale Wistar rats
(body weight: 200-220 g). Three weeks later, standardized gastric ulcers were produced
by cryoinjury as previously described [31]. In brief: fed rats were anesthetized with ether
and the abdomen was opened by median incision. The serosal surface ofthe posterior wall
of the midcorpus was injured by cryoprobe (outside diameter 6.5 mm, cooled by gaseous
carbon dioxide to -60°C; Cryoprobe BM 250, Erbokryo 12, Ruegge Medical, Baden,
Switzerland) to the wall for 45 s. The lesion was allowed to thaw naturally and then the
abdomen was rinsed with isotonic saline solution and closed with catgut and silk sutures:
The rats were kept under normal laboratory conditions with free access to water and a
standard pelleted rat diet (Naphag, Gossau, Switzerland). At 24 h after cryoinjury, the
35Halter et al.: Gastric ulcerogenicity versus ulcer healing
ulcer size was measured by video endoscopy [11]. Only those rats with round ulcers with
an ulcer diameter of4.5-6.5 mm were allocated to the trial.
Study drugs: Omeprazole was provided byAB Hassle (Molndal, Sweden), nitrofenac
by Pharmaceutical Discovery Service (Monza, Italy), and tebufelone from Procter &
Gamble Pharmaceuticals (Cincinnati, Ohio, USA). Indomethacin (Indocid for injection)
was obtained from Merck Sharp & Dohme and diclofenac sodium from Sigma.
Study design: At 24 h after cryoinjury, 30 rats were randomly assigned to one of the
following six groups (5 rats each): (1) placebo (volume: 1 ml) intragastrically (i.g.) and
distilled water (volume: 0.25 ml) subcutaneously (s.c.) twice daily, (2) placebo i.g. and
indomethacin 0.5 mg/kg s.c. twice daily, (3) placebo i.g. twice daily and omeprazole 40
pmol/kg s.c. once daily, (4) placebo i.g. and indomethacin 0.5 mg s.c. twice daily and
omeprazole 40 ,umol/kg s.c. once daily, (5) tebufelone 1 mg/kg i.g. and distilled water s.c.
twice daily, (6) tebufelone 10 mg/kg i.g. and distilled water s.c. twice daily. Rats were
treated for 15 days.
Additional preliminary ulcer healing studies: At 24 h aftercryoinjury, forty-eight rats
were randomly assigned to one of the following six groups (eight rats each) and treated
twice daily for 15 days: (1) placebo i.g. and distilled water s.c. twice daily, (2) placebo i.g.
and indomethacin 0.5 mg/kg s.c. twice daily, (3) placebo i.g. twice daily and omeprazole
40 pmol/kg s.c. once daily, (4) diclofenac 2.5 mg/kg i.g. and distilled water s.c. twice
daily, (5) nitrofenac 3.75 mg/kg i.g. and distilled water s.c. twice daily, (6) indomethacin
0.5 mg/kg s.c. twice daily plus omeprazole 40 pmol/kg s.c. once daily. Rats were treated
for 15 days.
Video endoscopy: Endoscopic examinations were performed on rats with a cannula
(implanted into the rumen) through which a video endoscope (arthroscope, outer diame-
ter: 4 mm, 300 side-view, Stortz, Tuttlingen, Germany; Video camera OTV-F Olympus,
Tokyo, Japan) was inserted. In the first part ofthe study, video endoscopy was performed
on days 1, 3, 6, 8, 10, 13, and 15 without fasting. In the additional preliminary part ofthe
study, video endoscopy was performed on days 3, 8, and 15. Rats were immobilized in
Bollman cages without anesthesia. They did not show any sign of discomfort during
endoscopy. Food present in the stomach was washed out through the gastric cannula. For
the ulcer size measurement, a round piece of calibration paper (diameter 4 mm) was
placed close to the ulcer crater. Ulcer size was measured and compared with the calibra-
tion paper as described [8]. The ulcer diameter was calculated according to the formula:
diameter = 2 x square root of(area/(X). To eliminate the influence of the initial variation
in ulcer diameter, we expressed ulcer healing as a percent reduction of the ulcer diame-
ter per day. Ulcer healing rate on a given day was [ulcer diameter on day "x"] - [ulcer
diameter on day "y"] / [y - x] in percent.
Generation ofprostanoids: Prostaglandin (6-keto-PG-FIa)and thromboxane B2 gener-
ation were measured one hour after drug administration on day 15. Gastric mucosal spec-
imens (approximately 30 g) were obtained at sacrifice, carefully blotted and the wet
weight was measured. The tissue specimens were then incubated in 0.6 ml ofoxygenated
Tyrode's solution at 37°C for 10 min. Release of 6-keto-PG-Fla (stable metabolite of
prostacyclin) into the incubation medium was determined using a specific radioimmune
assay as described previously [32, 33]. In the second part of the study, thromboxane B2
synthesis by the blood was additionally determined as describedpreviously [34]. To assess
changes during treatment, plasma gastrin was measured by radioimmune assay in fed rats
before and after treatment as described [35].
Statistics: The significance of differences was tested by Mann Whitney U-test or by
one-way analysis of variance [36]. Probability values of p < .05 were regarded as signifi-
cant. Results are expressed as mean + SEM.
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RESULTS
L. Comparative ulcerogenicity oftebufelone andreference NSAIDs in arthritic rats with an
intact stomach
At the lowest dose of tebufelone (15 mg/kg) no detectable gastric mucosal damage
was observed when this was given as either a single dose (Table 1) or even when given as
daily doses for 5 days (Table 2).
There did not appear to be a marked difference in the gastric mucosal damage
induced by tebufelone, alone, at 2 hr compared with 4 hr following single doses of the
drug. In contrast, indomethacin given at doses which are approximately equipotent in
Table 1. NSAID-induced gastric lesions in faster arthritic rats: single dose studies.
Treatment Time No. of lesions Severity of lesions** No. of animals
(hours) (means + S.E.M.) (means ± S.E.M.)
Control
I ml H20 2 0 0 4
4 0 0 4
Indomethacint
3 mg/kg 4 7.7 ± 1.9* 23.0±9.5* 3
15 mg/kg 27.7± 3.2* 68.0 ± 13.5* 3
30 mg/kg 39.0 ± 4.0* 156 ± 46.2* 3
Tebufelone
15 mg/kg 2 0 0 5
50 mg/kg 0.8 ± 0.2 0.4 ± 0.18 5
250 mg/kg 13.9 ± 1.1* 47.4 ± 12.0* 6
500 mg/kg 1.2 ± 1.16 4.7 ± 4.6 6
15 mg/kg 0 0 6
50 mg/kg 4 10.2 ±1.0* 34.2 ± 8.9* 6
250mg/kg 13.1 ± 1.1* 47.4±12.0* 5
500 mg/kg 20.0 ± 3.4* 62.7 ± 20.0* 6
* Denotes statistically significant increase in mucosal damage compared with controls (Mann-
Whitney U-test). ** Severity ofdamage determined from average width of lesions in mm.
t Peak lesion development with indomethacin occurs at 4 hr in this model.
anti-inflammatory activity with tebufelone (in the chronic adjuvant arthritis model in rats;
S.P. Sirko, K.D. Rainsford, unpublished studies) at a dose of 3 mg/kg produced marked
acute mucosal damage (Table 1). Furthermore, the dose response for acute gastric lesions
was appreciably lower with the single dose treatment of tebufelone than with
indomethacin (Table 1).
Following 5-day treatment there was more damage evident with 50 mg/kg tebufelone
than after a single dose ofthis drug. No intestinal mucosal damage was evident following
repeated doses of tebufelone for 5 days whereas indomethacin produced severe injury to
the extent that at the high dose of3 mg/kg/day all animals had died with peritonitis (Table
2).
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Table 2. NSAIDs-induced gastric lesions in fasted arthritic rats: repeated daily dosing for 5
days.
Treatment Dose N No of lesions Severity*
Tebufelone 15 mg/kg day 6 0 0
50 mg/kg dayt 6 4.9 (1.1) 33.3 (22.0)
Indomethacin 1 mg/kg dayt 6 8.8 (1.4) 2.1 (3.0)
3 mg/kg day 6 **in small intestine
all grade 4.0+
dead with peritonitis
Values are means (standard errors). t Statistically significant increase in mucosal lesion numbers
compared with controls (Mann Whitney U-test, p < .05). * Severity of gastric lesions was deter-
mined from the average width of lesions (mm). ** Severity of intestinal lesions graded 0-5.
ll. Ulcer healing studies with new generation and reference NSAIDs
The 25 rats remained well during the total study period and had the same weight gain
in all groups (290 ± 3 g at start and 315 ± 4 g at day 15).
Sequential analysis ofulcer healing by video endoscopy: The mean ulcer diameter on
day 1 was 5.7 ± 0.1 mm. The initial ulcer did not show significant differences between the
groups. In the placebo treated rats, healing rate was relatively rapid during days 3-8.
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Figure 1. Ulcer healing curve assessed by video endoscopy. (a) The data indicate mean percent-
age residual ulcer size ± SEM over the 7 observation time points. (b) Residual ulcer size on day 15
in percentage ofthe initial ulcer size on day 1. Omeprazole (*)treated rats showed significant reduc-
tion ofulcer diameter during days 6-15. Compared with placebo (A), tebufelone and indomethacin
(O) significantly increased ulcer size which became progressively apparent during days 13-15 (teb-
ufalone: 2 x 10mg/kg(U); 2 x 1 mg/kg(m). Indomethacin with omeprazole (A) showed significantly
decreased ulcer size compared with placebo on days 8 and 10, but not on days 13 and 15. * p < .05
vs. placebo (ANOVA).
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Then, healing velocity decreased during days 8-10, particularly during days 10-15.
Omeprazole significantly accelerated ulcer healing rate during days 3-8 and showed a sig-
nificantly decreased ulcer size compared with placebo from day 6 onward (Figures 1 and
2).
Tebufelone and indomethacin showed significantly increased ulcer size compared
with placebo on day 15. Omeprazole reversed indomethacin-induced delay ofulcer heal-
ing to placebo healing speed (Figure 1).
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Figure 2. Ulcer healing rate-time curve. The data (mean ± SEM) are expressed as percentage size
reduction per day. Left panel: Compared with placebo (A), omeprazole (*) treated rats showed sig-
nificantly accelerated healing during days 3-8, but not during days 8-15. Rats treated with
indomethacin (O) showed significant decreased healing during days 10-15. Right panel: Compared
with placebo (A), tebufalone high dose (2 x 10 mg/kg *) but not low dose (2 x 1 mg/kg m) showed
significant decreased healing during days 10-15. * p < .05 vs. placebo (ANOVA).
In addition to the ulcer healing curve, we assessed the ulcer healing rate in different
phases ofulcer healing. These analyses showed that omeprazole accelerated ulcer healing
in the early phase (days 3-8) while indomethacin and tebufelone delayed ulcer healing in
the late phase (days 10-15) (Figure 2).
Plasma gastrin level: Gastrin plasma levels in fed rats were 160 ± 7.1 pmolIl before
treatment. Gastrin plasma levels were not affected by treatment with any of the tested
NSAIDs. Compared with placebo, plasma gastrin levels were increased by 3.4-fold in rats
treated with omeprazole.
Additional preliminary ulcer healing studies: In placebo group, ulcer diameters on
days 3, 8, and 15 were 3.8 ± 0.2, 2.2 ± 0.1, and 0.9 ± 0.1 mm, respectively. On day 15,
ulcer size was significantly smaller in omeprazole and larger in indomethacin, diclofenac,
and nitrofenac groups (Figure l/Table 3); ex-vivo 6-keto-PG-Fla (prostaglandin generation
in gastric mucosa and thromboxane B2 synthesis by blood were significantly reduced by
indomethacin, diclofenac, and nitrofenac (Table 3).
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Table 3. Effects ofNSAIDs on videoendoscopic ulcer size, prostanoid synthesis, and
histologic healing parameters
Indomethacin Indomethacin + Diclofenac Nitrofenac
Glyceryl Trinitrate
Percentage change compared with placebo *
Videoendoscopic
ulcer size on day 15 + 81 % + 77 % +111 % + 91 %
Gastric 6-keto-PGFIa - 42 % - 45 % - 88 % - 59 %
Thromboxane B2 in blood - 76 % - 71 % - 67% -53 %
Angiogenesis in ulcer bed - 55 % - 44 % - 59 % - 53 %
Thickness ofulcer base + 78 % + 75% + 94 % + 84 %
Gap between musc. mucosae + 65 % + 68 % + 72 % + 63 %
* All values differ significantly from the placebo: p < .05 (ANOVA)
Ex vivo 6-keto-PG-Fla prostaglandin generation in gastric mucosa and thromboxane B2 synthesis by
blood were significantly reduced by indomethacin, diclofenac, and nitrofenac.
DISCUSSION
The observations in this study on rats with an intact stomach suggest that tebufelone
is less ulcerogenic than indomethacin when given at doses with equipotent anti-inflam-
matory activity. This is not only evident in the gastric mucosa but particularly for the small
intestinal mucosa. The small bowel toxicity of indomethacin is likely to be related to the
property ofthis drug to undergo enterohepatic recirculation since it is well established that
this enhances ulcerogenicity in the small intestine [37]. In contrast, ulcer healing was sig-
nificantly delayed by tebufelone both at daily doses of2 and 20 mg/kg tebufelone with the
high dose to a similar degree as by 1 mg/kg indomethacin, which is the highest dose with
0 I-
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can be repeatedly administered to rats, since higher doses almost invariably induce small
bowel perforation [11]. In the ulcerogenicity studies, tebufelone 15 mg/kg did not show
any evidence of mucosal damage in either the stomach or the intestinal tract after single
or repeated daily dosing of the drug in a very sensitive model ofNSAID-induced gastro-
intestinal damage [27].
Indeed both the new generation NSAIDs tebufelone and nitrofenac delayed ulcer
healing to a similar degree as the conventional NSAIDs, indomethacin and diclofenac.
The ulcer healing studies were performed in a well validated chronic model. This is
the only published ulcer healing model which allows direct assessment ofthe entire heal-
ing dynamics using the video endoscopy technique. The reference drugs, omeprazole and
indomethacin, clearly and reproducibly modified the ulcer healing curve in an opposite
manner. Profound acid inhibition by omeprazole predominantly accelerates ulcer healing
during in the early healing phase, such as during days 3-8 [11, 38, 39], a finding which is
consistent with the observation that histamine-induced hyperacidity delays ulcer healing
in pigs only in the early phase [40]. Similarly profound acid inhibition with omeprazole
accordingly accelerates ulcer healing predominantly during the early (first two weeks)
healing phase [16]. Indomethacin interferes with ulcer healing predominantly in the early
phase, but by contrast with omeprazole this modifies the ulcer healing curve only after a
time-lag of 7-10 days [11, 39].
The reason why ulcerogenicity and interference with healing diverge with some
NSAIDs is not entirely clear. The degree ofinhibition ofprostanoid synthesis did not sig-
nificantly differ between tebufelone and the two conventional NSAIDs, indomethacin and
diclofenac. Modification of tissue prostaglandin levels, however, predominantly affects
mucosal protective mechanisms which are predominantly mediated by preservation ofthe
microvascular system and/or stimulation of mucus-bicarbonate production. In contrast,
ulcer healing is predominantly affected by the triad ofinterference withepithelial cell pro-
liferation, angiogenesis, and proliferation and function of myofibroblasts. Indomethacin
has been shown to delay ulcer healing by decreasing epithelial cell proliferation, angio-
genesis in the ulcer bed, and interference with remodelling ofthe granulation tissue in the
ulcer bed [ 1]. Since both drugs affect the late phase of ulcer healing, it seems likely that
similar mechanisms are responsible for the delaying effect of tebufelone and
indomethacin on ulcer healing.
Elliott et al. [20] have reported that the nitrite-oxide releasing compound, nitrofenac,
accelerated healing of gastric ulcers in the rat using the acetic-acid model It is, however,
ofparticular interest that diclofenac which was administered at the same dose as used in
this study did not delay ulcer healing in their model [39]. This, however, comes to no sur-
prise since both diclofenac and nitrofenac were only applied in the second week after ulcer
induction only for 7 days in a time period when NSAIDs interferes less with healing
dynamics, while the delay is four-fold if the application is initiated shortly after ulcer
induction and maintained for a two week period [39]. In our model indomethacin,
diclofenac and nitrofenac similarly decreased gastric prostaglandin synthesis and throm-
boxane synthesis by the blood, delayed ulcer healing predominantly in the second week,
and interfered with angiogenesis and maturation of granulation tissue in the ulcer base.
Overall the deleterious effects in our model ofboth diclofenac alone or as in the esterified
nitro-donor, nitrofenac, is more pronounced than the possible beneficial effects of nitric
oxide.
In conclusion, in this reproducible chronic ulcer model, where reference drugs clear-
ly affect the ulcer healing curve, the two new generation NSAIDs tested negatively inter-
fere with gastric ulcerhealing to a similar extent as indomethacin. The better performance
of an NSAID in ulcerogenicity studies does not allow extrapolation of reduced interfer-
ence with ulcer healing.
4142 Halter et al.: Gastric ulcerogenicity versus ulcer healing
ACKNOWLEDGEMENTS: This study was sponsored by a joint grant from the Swiss National
Science Foundation (No. 83BC-041834) and the British Council. The costs were covered in part by
Procter & Gamble Pharmaceuticals, Cincinnati, Ohio, USA.
REFERENCES
1. Halter, F., Hurlimann, S., and Inauen, W. Pathophysiology and clinical relevance ofHelcobacter
pylori. Yale J. Biol. Med;1992,65:625-638.
2. Hawkey, C.J. Non-steroidal anti-inflammatory drugs and peptic ulcers. Br. Med. J.
300:278-84, 1990.
3. Peura, D.A. and Graham, D.Y. Helicobacter pylori: consensus reached: peptic ulcer is on the
way to becoming an historic disease [editorial], Am. J. Gastroenterol. 89:1137-1139, 1994.
4. Armstrong, H.P. and Blower, A.L. Non-steroidal anti-inflammatory drugs and life-threatening
complications of peptic ulceration. Gut 28:527-532, 1987.
5. Somerville, K., Faulkner, G., and Langman, M. Non-steroidal anti-inflammatory drugs and
bleeding peptic ulcer. Lancet 1:462-464, 1986.
6. Halter, F., Weber, B., Huber, T., Eigenmann, F., Frey, M.P., and Ruchti, C. Diaphragm disease
of the ascending colon. Association with sustained-release diclofenac. J. Clin. Gastroenterol.
16:74-80, 1993.
7. Inauen, W., Wyss, P.A., Kayser, S., Baumgartner, A., Schurer-Maly, C.C., Koelz, H.R., and
Halter, F. Influence ofprostaglandins, omeprazole, and indomethacin on healing ofexperimen-
tal gastric ulcers in the rat. Gastroenterol. 95:636-641, 1988.
8. Wang, J.Y, Yamasaki, S., Takeuchi, K., and Okabe, S. Delayed healing of acetic acid-induced
gastric ulcers in rats by indomethacin. Gastroenterol. 96:393-402, 1989.
9. Hirose, H., Takeuchi, K., and Okabe, S. Effect of indomethacin on gastric mucosal blood flow
around acetic acid induced gastric ulcers in rats. Gastroenterol. 100:1259-1265, 1991.
10. Graham, D.Y, Agrawal, N.M., and Roth, S.H. Prevention ofNSAID-induced gastric ulcer with
misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 2:1277-1280, 1988.
11. Schmassmann, A., Tarnawski, A., Peskar, B.M.,Varga, L., Flogerzi, B., and Halter, F. Sequential
assessment ofgastric ulcer healing in rats: reversal ofindomethacin-induced effects by omepra-
zole. Am. J. Physiol. 268:G276-G285, 1994.
12. Levi, S., Goodlad, R.A., Lee, C.Y., Stamp, G., Walport, M.J., Wright, N.A., and Hodgson, H.J.F.
Inhibitory effect of non-steroidal anti-inflammatory drugs on mucosal cell proliferation associ-
ated with gastric ulcer healing. Lancet 336:840-843, 1990.
13. Ogihara,Y. and Okabe, S. Mechanism by which indomethacin delays gastric ulcer healing in the
rat: Inhibited contraction ofthe ulcer base. Japan. J. Pharmacol. 61:123-131, 1993.
14. Graham, D.Y., Smith, J.L., Spjut, H.J., and Torres, E. Gastric adaptation studies in humans dur-
ing continuous aspirin administration. Gastroenterol. 95:327-333, 1988.
15. Hawkey, C.J. and Walt, R.P. Prostaglandins for peptic ulcer. A promise unfulfilled. Lancet
2,1084-1087, 1986.
16. Walan, A., Bader, J.P., Classen, M., Lamers, C.B.H.W., Piper, D.W., Rutgersson, K., and
Eriksson, S. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients
with benign gastric ulcer. N. Engl. J. Med. 320:69-75, 1989.
17. Wang, J.Y., Nagai, H., and Okabe, S. Effect of omeprazole on delayed healing of acetic acid-
induced gastric ulcers in rats. Japan. J. Pharmacol. 54:82-85, 1990.
18. Sirko, S.P., Schindler, R., Doyle, M.J., Weissman, S.M., and Dinarello, C.A. Transcription,
translation and secretion ofinterleukin 1 and tumor necrosis factor: effects oftebufelone, a dual
cyclooxygenase/5-lipoxygenase inhibitor. Eur. J. Immunol. 21:243-250, 1991.
19. Wallace, J.L., Reuter, B., Cicala, C., McKnight, W., Grisham, M.B., and Cirino, G. Novel non-
steroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in
the rat. Gastroenterol. 107:173-179, 1994.
20. Elliott, S.N., McKnight, W., Cirino, G., and Wallace, J.L. A nitric oxide-releasing nonsteroidal
anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterol. 109:524-530,
1995.
21. Wallace, J.L., Pittman, Q.J., andCirino, G: Nitric oxide-releasing NSAIDs: a novel class ofGI-
sparing anti-inflammatory drugs. Agents Actions; 46(Suppl):121-129, 1995.
22. Benoni, G., Terzi, M., Adami, A., Grigolini, L., Del Soldato, P., and Cuzzolin, L. Plasma con-
centrations and pharmacokinetic parameters of nitrofenac using a simple and sensitive HPLC
method. J. Pharm. Sci. 84:93-95, 1995.Halter et al.: Gastric ulcerogenicity versus ulcer healing 43
23. Wallace, J.L., Reuter, B., Cicala, C., McKnight, W., Grisham, M., and Cirino, G. A diclofenac
derivative without ulcerogenic properties. Eur. J. Pharmacol. 25:249-255, 1994.
24. Conforti, A., Donini, M., Brocco, G., Del Soldato, P., Benoni, G., and Cuzzolin, L. Acute anti-
inflammatory activity and gastrointestinal tolerability of diclofenac and nitrofenac. Agents
Actions 40:176-180, 1993.
25. Reuter, B.K., Cirino, G., and Wallace, J.L. Markedly reduced intestinal toxicity of a diclofenac
derivative. Life Sci. 55:1-8, 1994.
26. Cuzzolin, L., Conforti, A., Donini, M., Adami, A., Del Soldato, P., and Benoni, G. Effects on
intestinal microflora, gastrointestinal tolerability and anti-inflammatory efficacy of diclofenac
and nitrofenac in adjuvant arthritic rats. Pharmacol. Res. 29:89-97, 1994.
27. Rainsford, K.D. Animal models for the assay of gastrointestinal toxicity of anti-inflammatory
drugs. In: Handboolk of Animal Models for the Rheumatic Diseases, Vol. II. Eds. Greenwald
12A, Diamond, H.S. CRC Press, Boca Raton, FL,1988, pp. 181-206.
28. Rainsford, K.D. Mechanisms ofgastrointestinal ulceration from non-steroidal anti-inflammato-
ry drugs: a basis for use and development of protective agents. In: Side Effects ofAnti-inflam-
matory Drugs - 3. Eds. Rainsford, K.D. and Velo, G.P. KluwerAcademic Publishers, Lancaster;
1992, pp. 97-114.
29. Whitehouse, M.W., Orr, K.J., Beck, F.W.J., and Pearson, C.M. Freund's adjuvants: relationship
of arthritogenicity and adjuvanticity in rats to vehicle composition. Immunol. 27:311-3301974.
30. Bjarnason, I. Non-steroidal anti-inflammatory drug-induced small intestinal inflammation in
man. Recent Adv. Gastroenterol. 7:23-46, 1988.
31. Meyrat, P., Baumgartner, A., Kappeler, M., and Halter, F. Simple gastroscopy technique in the
rat. Dig. Dis. Sci. 29:327-329, 1984.
32. Peskar, B.M., Lange, K., Hoppe, U., and Peskar, B.A. Ethanol stimulates formation of
leukotriene C4 in rat gastric mucosa. Prostaglandins 31:283-293, 1986.
33. Peskar, B.M., Hoppe, U., Lange, K., and Peskar, B.A. Effects ofnon-steroidal anti-inflammato-
ry drugs on rat gastric mucosa leukotriene C4 and prostanoid release: relation to ethanol-
induced injury. Br. J. Pharmacol. 93:937-943, 1988.
34. Wallace, J.L., McCafferty, D.M., Carter, L., McKnight, W., and Argentieri, D. Tissue-selective
inhibition ofprostaglandin synthesis in rat by tepoxalin: anti-inflammatory without gastropathy.
Gastroenterol. 105:1630-1636, 1993.
35. Witzel, L., Heitz, P.U., Halter, F., Olah, A.J., Varga, L., Werner, O., and Hacki, W.H. Effects of
prolonged administration ofmetiamide on serum gastrin, gastrin content ofthe antrum and gas-
tric corpus and G-cell population in the rat. Gastroenterol. 76:945-949, 1979
36. Sachs, L. Angewandte Statistik. Berlin, Heidelberg, New-York; Springer; 1973.
37. Satoh, H., Guth, P.H., and Grossman, M.I. Role of food in gastrointestinal ulceration produced
by indomethacin in the rat. Gastroenterol. 83:210-215, 1982.
38. Scheurer, U., Witzel, L., Halter, F., Keller, H.M., Huber, R., and Galeazzi, R. Gastric and duo-
denal ulcer healing under placebo treatment. Gastroenterol. 72:838-841, 1977.
39. Schmassmann, A., Tamawski, A., Flogerzi, B., Sanner, M., Varga, L., and Halter, F. Dynamics
ofdrug interference with healing ofexperimental gastric ulcers. Eur. J. Gastroenterol. Hepatol.
5(Suppl. 3):S13-S20, 1993.
40. Halter, F., Barbezat, G.O., Van Hoorn-Hickman, R., and Van Hoom, W.A. Healing dynamics of
traumatic gastric mucosal defects in the normal and hyperacid stomach. Dig. Dis. Sci. 25:916-
920, 1980